Concepedia

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara, Achim Berthele, Celia Oreja‐Guevara, Ho Jin Kim, Ichiro Nakashima, Michael Levy, Murat Terzi, N. А. Totolyan,

Multiple Sclerosis and Related Disorders · 2020 · 40 citations · 22 references

DOIFull text

Open access

Concepts

References

22

The clinical course of neuromyelitis optica (Devic’s syndrome)

Dean M. Wingerchuk, William F. Hogancamp, Peter C. O’Brien et al. · Neurology · 1999 · 1.8K citations

, , +12

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Achim Berthele, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 846 citations · Full text

, , +17

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

An open label study of the effects of rituximab in neuromyelitis optica

Bruce Cree, Sara Lamb, Katherine A. Morgan et al. · Neurology · 2005 · 646 citations

, , +10

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice

Samira Saadoun, Patrick Waters, B. Anthony Bell et al. · Brain · 2010 · 543 citations · Full text

, , +15